AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX RNAi gene-silencing platform across all human therapeutic areas. This strategic move allows AviadoBio to leverage the innovative capabilities of the vMiX platform, which has shown promise in various applications, enhancing its portfolio in gene therapy.
The extension of this licence signifies a pivotal moment for AviadoBio as it seeks to expand its footprint in the rapidly evolving field of RNA interference. By gaining access to the vMiX platform, the company is positioned to explore a wider range of therapeutic options, potentially accelerating the development of novel treatments for complex diseases that currently lack effective solutions.
This collaboration not only underscores the growing importance of RNAi technologies in modern medicine but also reflects the increasing trend of partnerships between biotech firms and academic institutions. As AviadoBio integrates the vMiX platform into its research and development pipeline, industry stakeholders will be closely monitoring the outcomes of this partnership and its implications for future therapeutic advancements.
Start your 7-day trial and see what the database can do →
